×
About 2,667 results

ALLMedicine Systemic Mastocytosis Center

Research & Reviews  1,047 results

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic...
https://doi.org/10.1016/j.jaci.2020.03.044
The Journal of Allergy and Clinical Immunology; Hartmann K, Gotlib J et. al.

May 21st, 2020 - Advanced systemic mastocytosis (advSM) is characterized by the presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in various tissues, leading to severe symptoms and organ damage, eg, cytopenias, liver dys...

A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Invo...
https://doi.org/10.12659/AJCR.923354
The American Journal of Case Reports; Ibrahim FA, Abdulla MAJ et. al.

May 12th, 2020 - BACKGROUND Single or multiple cell line dysplasia is a characteristic feature of myelodysplastic syndrome. However, significant dysgranulopoiesis is not a feature of chronic myeloid leukemia (CML). Systemic mastocytosis (SM) with an associated hem...

Study of Mast Cell Precursors
https://clinicaltrials.gov/ct2/show/NCT00001756

May 3rd, 2020 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and path...
https://doi.org/10.1016/j.blre.2020.100693
Blood Reviews; Ozturk K, Cayci Z et. al.

Apr 26th, 2020 - Systemic mastocytosis (SM) is a hematologic disease with a wide range of clinical courses ranging from an indolent condition with normal life expectancy to exceedingly aggressive disorder with a poor prognosis. The symptoms and signs of SM result ...

Systemic mastocytosis associated with Hodgkin's lymphoma in a 4-year-old child.
https://doi.org/10.1111/pde.14183
Pediatric Dermatology REFERENCES; Srinivas SM, Agarwal R et. al.

Apr 21st, 2020 - Systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease (SM-AHN) represents a specific subtype of mastocytosis and is extremely rare in children. We describe a 4-year-old child with systemic mastocytosis associated w...

see more →

Guidelines  2 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JNCCN; Gotlib J, Gerds AT et. al.

Dec 13th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/16/12/1500.full
Gotlib, J.

Nov 30th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt.

see more →

Drugs  243 results see all →

Clinicaltrials.gov  1,329 results

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic...
https://doi.org/10.1016/j.jaci.2020.03.044
The Journal of Allergy and Clinical Immunology; Hartmann K, Gotlib J et. al.

May 21st, 2020 - Advanced systemic mastocytosis (advSM) is characterized by the presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in various tissues, leading to severe symptoms and organ damage, eg, cytopenias, liver dys...

Ranitidine - ranitidine solution-Hi-Tech Pharmacal Co., Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7485b07-7ac0-44fe-a713-1e066c9043a8

May 18th, 2020 - Ranitidine is indicated in: 1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks....

A Rare Case of Systemic Mastocytosis with Associated Hematologic Neoplasm (SM-AHN) Invo...
https://doi.org/10.12659/AJCR.923354
The American Journal of Case Reports; Ibrahim FA, Abdulla MAJ et. al.

May 12th, 2020 - BACKGROUND Single or multiple cell line dysplasia is a characteristic feature of myelodysplastic syndrome. However, significant dysgranulopoiesis is not a feature of chronic myeloid leukemia (CML). Systemic mastocytosis (SM) with an associated hem...

Study of Mast Cell Precursors
https://clinicaltrials.gov/ct2/show/NCT00001756

May 3rd, 2020 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and path...
https://doi.org/10.1016/j.blre.2020.100693
Blood Reviews; Ozturk K, Cayci Z et. al.

Apr 26th, 2020 - Systemic mastocytosis (SM) is a hematologic disease with a wide range of clinical courses ranging from an indolent condition with normal life expectancy to exceedingly aggressive disorder with a poor prognosis. The symptoms and signs of SM result ...

see more →

News  41 results

Gene-targeting therapy shown to reduce mastocytosis symptoms
https://www.mdedge.com/familymedicine/article/219888/asthma/gene-targeting-therapy-shown-reduce-mastocytosis-symptoms?channel=39313
CHEST Physician; Richard Mark Kirkner

Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.

Inhibitor can improve symptoms of systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/190755/cythemias/inhibitor-can-improve-symptoms-systemic-mastocytosis?channel=50517
Jen Smith

Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.

A Case of Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disease at VA Pittsburgh Healthcare System
https://www.mdedge.com/fedprac/avaho/article/174895/lymphoma-plasma-cell-disorders/case-systemic-mastocytosis-associated
Liman AD, Gandhi A et. al.

Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.

Avapritinib produces durable responses in SM
https://www.mdedge.com/hematology-oncology/article/184888/leukemia-myelodysplasia-transplantation/avapritinib-produces-durable
HT Staff

Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.

Avapritinib yields high response rate in patients with systemic mastocytosis
https://www.mdedge.com/hematology-oncology/article/153966/myelodysplastic-syndrome/avapritinib-yields-high-response-rate
Andrew D. Bowser

Dec 10th, 2017 - ATLANTA – An oral investigational drug with specific activity against a mutation frequently found in advanced systemic mastocytosis (ASM) produced clinical responses in the majority treated patients, according to preliminary data presented at the.

see more →

Patient Education  5 results see all →